title: Efficacy of ex vivo purging for autologous bone marrow transplantation in the treatment of acute nonlymphoblastic leukemia.
abstract: We used an in vitro measure of drug activity to predict the efficacy of ex vivo purging of leukemic cells from autologous bone marrow grafts. We previously found that the myeloid progenitor cell (CFU-GM) content of the marrow grafts after ex vivo purging with 4-hydroperoxycyclophosphamide (4-HC) correlates with time to hematologic recovery after autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia. We observed that variable red blood cell concentration of the bone marrow incubation mixture results in differential cytotoxic activity of 4-HC. The CFU-GM content of the graft after the ex vivo treatment is a measure of this 4-HC activity. We analyzed the disease-free survival of 45 patients with acute nonlymphoblastic leukemia undergoing autologous bone marrow transplantation with 4-HC purged grafts. Patients who relapsed after transplantation had 4.2 +/- 1.1% of graft CFU-GM surviving the ex vivo purge, compared with 1.1 +/- 0.4% for patients who achieved a sustained remission (P = .06). Twenty-three patients with a CFU-GM content after 4-HC purging of greater than 1% of the pretreatment value had an actuarial disease-free survival of 12%, compared to 36% for 22 patients with a less than or equal to 1% CFU-GM content after purging (P = .006). Therefore, percent CFU-GM survival as a measure of 4-HC cytotoxicity identified a group of patients with insufficient purging. Although no randomized clinical trials have documented the need for ex vivo purging, our results suggest that effective bone marrow purging is important for the optimal application of autologous transplantation in the treatment of acute nonlymphoblastic leukemia.
authors.affiliation: Johns Hopkins Oncology Center, Baltimore, MD 21205.
authors.forename: S D
authors.initials: SD
authors.lastname: Rowley
authors.forename: R J
authors.initials: RJ
authors.lastname: Jones
authors.forename: S
authors.initials: S
authors.lastname: Piantadosi
authors.forename: H G
authors.initials: HG
authors.lastname: Braine
authors.forename: O M
authors.initials: OM
authors.lastname: Colvin
authors.forename: J
authors.initials: J
authors.lastname: Davis
authors.forename: R
authors.initials: R
authors.lastname: Saral
authors.forename: S
authors.initials: S
authors.lastname: Sharkis
authors.forename: J
authors.initials: J
authors.lastname: Wingard
authors.forename: A M
authors.initials: AM
authors.lastname: Yeager
mesh_terms: D000367:Age Factors; D001853:Bone Marrow / Q000187:drug effects; D016026:Bone Marrow Transplantation; D003114:Colony-Forming Units Assay; D003520:Cyclophosphamide / Q000031:analogs & derivatives / Q000627:therapeutic use; D006412:Hematopoietic Stem Cells / Q000187:drug effects; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D011379:Prognosis; D014182:Transplantation, Autologous
chemical_list: D003520:Cyclophosphamide; C011272:perfosfamide